856436-16-3

856436-16-3 structure
856436-16-3 structure
  • Name: JAK3 Inhibitor VI
  • Chemical Name: methanesulfonic acid,5-pyridin-3-yl-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
  • CAS Number: 856436-16-3
  • Molecular Formula: C19H17N3O4S
  • Molecular Weight: 383.42100
  • Catalog: Signaling Pathways Epigenetics JAK
  • Create Date: 2017-08-18 23:33:59
  • Modify Date: 2025-08-24 22:56:31
  • JI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC50s of ∼250 and ∼500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia[1].

Name methanesulfonic acid,5-pyridin-3-yl-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
Synonyms IN1284
(3Z)-5-pyridin-3-yl-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
Description JI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC50s of ∼250 and ∼500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia[1].
Related Catalog
Target

FLT3-D835H:4 nM (IC50)

FLT3-D835Y:8 nM (IC50)

FLT3-WT:40 nM (IC50)

JAK3:~250 nM (IC50)

c-Kit:~500 nM (IC50)

In Vitro JI6 (3-1000 nM; 1-4 days) 以剂量依赖性方式抑制 MV4-11 细胞的活力,IC50 值为 ∼25 nM[1]。 JI6 (1-2000 nM; 48 h) 有效抑制表达 FLT3-ITD,FLT3-D835Y 和 FLT3-D835H 的 HCD-57 细胞的活力,IC50 值为 ∼40 nM,对亲代 HCD-57 或表达 JAK2V617F 的细胞基本没有影响[1]。 JI6 (100-500 nM; 24 h) 在表达 FLT3-ITD 和 FLT3-D835Y 的 HCD-57 细胞中诱导细胞凋亡和细胞周期停滞[1]。 JI6 (50-500 nM; 3 h) 抑制表达 FLT3-ITD 和 FLT3-D835Y 的 HCD-57 细胞中 FLT3 及 ERK 和 Akt 的磷酸化[1]。 Cell Viability Assay[1] Cell Line: MV4-11, HL60, Karpas 299, and Jurkat cells Concentration: 3-1000 nM Incubation Time: 48 hours Result: Inhibited MV4-11 cells and no effects of JI6 on the three remaining cells at a concentration as high as 1 μM. Apoptosis Analysis[1] Cell Line: FLT3-ITD- and FLT3-D835Y-transformed HCD-57 cells Concentration: 100, 500 nM Incubation Time: 24 hours Result: Increased the percentage of apoptotic and necrotic cells and displayed no effects on the apoptosis of the parent HCD-57 cells. Cell Cycle Analysis[1] Cell Line: FLT3-ITD- and FLT3-D835Y-transformed HCD-57 cells Concentration: 100, 500 nM Incubation Time: 24 hours Result: Significantly reduced G2 and S phase cells and increased G1 phase cells in both FLT3-ITD and D835Y cells. Cell Viability Assay[1] Cell Line: FLT3-ITD- and FLT3-D835Y-transformed HCD-57 cells Concentration: 50, 100, 500 nM Incubation Time: 3 hours Result: Inhibited phosphorylation of FLT3, ERK1, ERK2 and Akt.
In Vivo JI6 (15 mg/kg; i.p. daily for 3 weeks) 抑制免疫缺陷小鼠体内表达 FLT3-D835Y 的 HCD-57 增殖并延长小鼠存活期[1]。 JI6 (25 mg/kg; p.o. daily for 3 weeks) 抑制 FLT3-ITD 敲入小鼠的骨髓增生表型[1]。 JI6 (100 mg/kg; a single i.p.) 在表达 FLT3-D835Y 的小鼠中显着抑制 FLT3 磷酸化和下游信号转导[1]。 Animal Model: NSG mice (10-12 weeks old, male) were implanted with FLT3-D835Y-transformed HCD-57 cells[1] Dosage: 15 mg/kg Administration: I.p. daily for 3 weeks Result: Reduced the spleen size and prolonged the survival of these mice.
References

[1]. Chen Y, et, al. Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene. 2016 Jun 9;35(23):2971-8.  

Molecular Formula C19H17N3O4S
Molecular Weight 383.42100
Exact Mass 383.09400
PSA 120.53000
LogP 4.29220
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.